La Merie

Biologics Blog with Useful Links

During our daily work we come across a lot of information which might be useful for our customers and visitors from the biopharmaceutical industry. This blog will try to facilitate access to interesting data, reports and other information related to biologics, but not limited to. In addition, we will present our point of view and comment news in a fair, but succinct way. We hope you will enjoy our contributions and will appreciate any helpful comment and response from you.

Sunday, 03 November 2013 11:16

Rare Diseases R&D Pipeline

Written by
By definition, rare disease are those disorders which affect less than 200,000 patients in the US. A new report lists the more than 450 compounds under development by US companies for treatment of rare diseases. The study was published by PhRMA, the Pharmaceutical Research and Manufacturers of America and can be downloaded at http://phrma.org/sites/default/files/pdf/Rare_Diseases_2013.pdf The range of rare diseases for which new drugs are being developing, is spanning from cancer…
Thursday, 24 October 2013 10:48

Growth of annual antibody sales from 2006 to 2012

Written by
October 24, 2013 I La Merie published in February 2007 for the first time a compilation of the annual sales of therapeutic proteins and antibodies. Since then, we released every year our list of TOP selling antibodies and proteins. You can find these annual reports published in our weekly newsletter R&D Pipeline News as a special edition in our online portal www.pipelinereview.com under FREE Reports. We thought you might find…
October 17, 2013 I Undoubtedly, antibodies are a hot area for biotech and pharma companies. Development of antibody therapeutics not only seems to have a lower attrition rate than that of small molecules (at least for toxicity reasons), but antibody products are extremely commercially successful. No wonder, that many companies are „jumping on the wagon" of antibodies. However, only a fraction of the companies is working on antibody molecules directed…
Tuesday, 08 October 2013 09:19

Vaccines in US clinical development 2013

Written by
October 8, 2013 I The association of America’s biopharmaceutical companies (the Pharmaceutical Research and Manufacturers of America: PhRMA) recently released the report „Medicines in Development for Vaccines„. The report states that US companies are developing 271 vaccines in clinical stages to prevent or treat a variety of diseases including allergy, neurological diseases, cancer, infectious diseases and some others. The vast majority of vaccines is being developed for infections diseases (51%)…
Page 2 of 2